Orlando, FL -- (SBWIRE) -- 09/05/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Opko Health Inc.(NYSE:OPK), VIVUS, Inc.(NASDAQ:VVUS).
Opko Health Inc.(NYSE:OPK) recently acquired Prolor Biotech. Prolor stockholders will receive 0.9951 Opko shares for every stock of Prolor held by them.
Should Investors Buy OPK After Yesterday’s Slump? Find Out Here
Prolor’s four late stage candidates in the areas of growth hormone deficiency, hemophilia, obesity and diabetes will now be part of Opko’s portfolio.
The company has been acquiring one company after another. In April this year, Opko bought a 10% stake in Russian pharmaceutical company, OAO Pharmsynthez. In March, Opko acquired Cytochroma Inc.
Opko had earlier acquired Brazilian pharmaceutical company, Silcon Comércio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltd, enabling it to strengthen its presence in Latin America.
In December 2012, the company had acquired Prost-Data, Inc., which ran its business as OURLab, a Nashville-based CLIA (Clinical Laboratory Improvement Amendments) laboratory, with phlebotomy sites across the U.S.
In Aug 2012, Opko stepped into the European market by acquiring Farmadiet, a Spanish company that was into pharmaceutical, nutraceutical, and veterinary products in Europe.
Meanwhile, VIVUS, Inc.(NASDAQ:VVUS) CEO and company director Anthony P. Zook has announced that he is resigning from his posts due to illness. New hire Seth H.Z. Fischer, a former executive at Johnson & Johnson, will take up both posts in his place.
Can Traders Buy VVUS After The Solid Rally? Get Free Trend Analysis Here
Chairman Michael Astrue said: "VIVUS is keeping Tony in its thoughts and we wish him a rapid recovery. We are grateful for his contributions and his willingness to work with Seth through mid-September 2013 to assist with the transition."
Welcoming Fischer to the company, he said that the board will ask him to focus on the following goals: "(1) expand use of Qsymia through targeted patient and physician education; (2) find the right partner for Qsymia; (3) quickly create a pathway for approval in Europe; and (4) eliminate expenses that are not essential to expanding use of Qsymia."
VIVUS shares didn’t show any adverse reaction, and in fact rose 3% to close at $12.90.
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)